Effects of glycaemic management on diabetic kidney disease.

about

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

P2860

Q47614541-08267DCD-98F3-4DBD-9E53-629BD97F6518

P2860

Effects of glycaemic management on diabetic kidney disease.

Item

http://www.wikidata.org/entity/Q39345204

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Effects of glycaemic management on diabetic kidney disease.

@en

Effects of glycaemic management on diabetic kidney disease.

@nl

type

Item

label

Effects of glycaemic management on diabetic kidney disease.

@en

Effects of glycaemic management on diabetic kidney disease.

@nl

prefLabel

Effects of glycaemic management on diabetic kidney disease.

@en

Effects of glycaemic management on diabetic kidney disease.

@nl

P1476

Effects of glycaemic management on diabetic kidney disease.

@en

P2093

Elif I Ekinci

http://www.w3.org/2001/XMLSchema#string

George Jerums

http://www.w3.org/2001/XMLSchema#string

Richard J MacIsaac

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)

Effects of intensive glucose lowering in type 2 diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

P304

172-186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4239/WJD.V8.I5.172

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28572879

http://www.w3.org/2001/XMLSchema#string

P932

5437616

http://www.w3.org/2001/XMLSchema#string

Effects of glycaemic management on diabetic kidney disease.

about

P2860

P2860

Effects of glycaemic management on diabetic kidney disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932